

**PE/Cyanine7 anti-human CD56 (NCAM) Recombinant**

**Catalog # /** 2594040 / 100 tests  
**Size:** 2594035 / 25 tests

**Clone:** QA18A21


**Isotype:** Mouse IgG1, κ

**Reactivity:** Human

**Preparation:** The antibody was purified by affinity chromatography and conjugated with PE/Cyanine7 under optimal conditions.

**Formulation:** Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide and 0.2% (w/v) BSA (origin USA)

**Concentration:** Lot-specific



Human peripheral blood lymphocytes were stained with anti-human CD3 FITC and anti-human CD56 (NCAM) recombinant (clone QA18A21) PE/Cyanine7 (left) or anti-mouse IgG1, κ PE/Cyanine7 isotype control (right).

**Applications:**

**Applications:** Flow Cytometry

**Recommended Usage:** Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is 5 μL per million cells in 100 μL staining volume or 5 μL per 100 μL of whole blood. It is recommended that the reagent be titrated for optimal performance for each application.

**Description:** CD56 is a single transmembrane glycoprotein also known as NCAM (Neural Cell Adhesion Molecule), Leu-19, or NKH1. It is a member of the Ig superfamily. The 140 kD isoform is expressed on NK cells and NK-T cells. CD56 is also expressed in the brain (cerebellum and cortex) and at neuromuscular junctions. Certain large granular lymphocyte (LGL) leukemias, small-cell lung carcinomas, neuronal derived tumors, myelomas, and myeloid leukemias also express CD56. CD56 plays a role in homophilic and heterophilic adhesion via binding to itself or heparin sulfate.

- Antigen References:**
1. Rosental B, *et al.* 2011. *J Immunol.* 187:5693. [PubMed](#)
  2. Correia DV, *et al.* 2011. *Blood.* 118:992. [PubMed](#)
  3. Schlecker E, *et al.* 2014. *Cancer Res.* 74:3429. [PubMed](#)
  4. Snyder JM, *et al.* 2014. *PLoS One.* 9:e107257. [PubMed](#)
  5. Siebert N, *et al.* 2014. *PLoS One.* 9:e107692. [PubMed](#)
  6. Rider P, *et al.* 2015. *J Immunol.* 195:1705-12. [PubMed](#)
  7. Davis ZB, *et al.* 2011. *J Vis Exp.* 49: 2668. [PubMed](#)
  8. Robin JD, *et al.* 2015. *J Vis Exp.* 95: 52307. [PubMed](#)
  9. Ames E, *et al.* 2015. *J Immunol.* 195: 4010-9. [PubMed](#)
  10. Laroni A, *et al.* 2016. *J Autoimmun.* 72:8-18. [PubMed](#)
  11. Pachnio A, *et al.* 2016. *PLoS Pathog.* 12:e1005832. [PubMed](#)
  12. Wouters K, *et al.* 2017. *Sci Rep.* 7:42665. [PubMed](#)